Stem cells for low blood counts after CAR-T
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have leukemia, lymphoma, or myeloma and had CAR-T therapy at least 3 weeks ago.
- Your blood counts are still very low (low white cells, low platelets, or low hemoglobin) at that point.
- You are well enough to be up and about (able to care for yourself).
- You have not had other cancer treatments in the past month that could affect your blood counts.
- You do not have a serious infection or other major health issues like heart, kidney, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
This study tests whether umbilical cord blood cells can help people whose blood counts stay dangerously low after immune-based cancer treatments like CAR-T or bispecific antibodies. The treatment aims to boost your blood cell recovery and reduce the need for transfusions.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
This trial tests a new approach for people with non-cancerous blood and immune system diseases. It uses your own engineered immune cells (CAR-T cells) to prepare your body for a stem cell transplant from a relative.
This trial tests whether infusing stem cells from umbilical cord blood can help your bone marrow recover and make healthy blood cells again after chemotherapy. The goal is to improve your blood counts and reduce the need for transfusions.
Hear when a new Immune Effector Cell Associated Hematotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.